Medical - Instruments & Supplies
Compare Stocks
5 / 10Stock Comparison
MBOT vs SSYS vs RBOT vs TRVI vs ISRG
Revenue, margins, valuation, and 5-year total return — side by side.
Computer Hardware
Medical - Devices
Biotechnology
Medical - Instruments & Supplies
MBOT vs SSYS vs RBOT vs TRVI vs ISRG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Computer Hardware | Medical - Devices | Biotechnology | Medical - Instruments & Supplies |
| Market Cap | $143M | $707M | $3M | $1.99B | $161.07B |
| Revenue (TTM) | $0.00 | $551M | $0.00 | $0.00 | $10.58B |
| Net Income (TTM) | $-13M | $-104M | $-42M | $-46M | $2.98B |
| Gross Margin | — | 43.6% | — | — | 66.3% |
| Operating Margin | — | -11.7% | — | — | 30.5% |
| Forward P/E | — | 69.8x | — | — | 43.8x |
| Total Debt | $111K | $27M | $8M | $753K | $303M |
| Cash & Equiv. | $3M | $95M | $3M | $19M | $3.37B |
MBOT vs SSYS vs RBOT vs TRVI vs ISRG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| Microbot Medical In… (MBOT) | 100 | 27.9 | -72.1% |
| Stratasys Ltd. (SSYS) | 100 | 65.8 | -34.2% |
| Vicarious Surgical … (RBOT) | 100 | 0.2 | -99.8% |
| Trevi Therapeutics,… (TRVI) | 100 | 348.6 | +248.6% |
| Intuitive Surgical,… (ISRG) | 100 | 191.7 | +91.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MBOT vs SSYS vs RBOT vs TRVI vs ISRG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MBOT lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, SSYS doesn't own a clear edge in any measured category.
RBOT is the #2 pick in this set and the best alternative if growth is your priority.
- 31.5% revenue growth vs MBOT's -17.1%
TRVI ranks third and is worth considering specifically for sleep-well-at-night.
- Lower volatility, beta 1.06, Low D/E 0.4%, current ratio 19.66x
- +111.0% vs RBOT's -94.1%
ISRG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.02
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.5% 10Y total return vs TRVI's 78.1%
- Beta 1.02, current ratio 4.87x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 31.5% revenue growth vs MBOT's -17.1% | |
| Value | Better valuation composite | |
| Quality / Margins | 28.2% margin vs SSYS's -18.9% | |
| Stability / Safety | Beta 1.02 vs RBOT's 1.92, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +111.0% vs RBOT's -94.1% | |
| Efficiency (ROA) | 14.8% ROA vs RBOT's -164.5%, ROIC 15.0% vs -116.2% |
MBOT vs SSYS vs RBOT vs TRVI vs ISRG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
MBOT vs SSYS vs RBOT vs TRVI vs ISRG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 2 of 6 categories
TRVI leads 1 • MBOT leads 0 • SSYS leads 0 • RBOT leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG and TRVI operate at a comparable scale, with $10.6B and $0 in trailing revenue. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to SSYS's -18.9%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $551M | $0 | $0 | $10.6B |
| EBITDAEarnings before interest/tax | -$14M | -$32M | -$42M | -$53M | $3.8B |
| Net IncomeAfter-tax profit | -$13M | -$104M | -$42M | -$46M | $3.0B |
| Free Cash FlowCash after capex | -$11M | -$8M | -$40M | -$32M | $2.8B |
| Gross MarginGross profit ÷ Revenue | — | +43.6% | — | — | +66.3% |
| Operating MarginEBIT ÷ Revenue | — | -11.7% | — | — | +30.5% |
| Net MarginNet income ÷ Revenue | — | -18.9% | — | — | +28.2% |
| FCF MarginFCF ÷ Revenue | — | -1.4% | — | — | +26.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -6.9% | — | — | +23.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +62.8% | +62.7% | +58.1% | -2.4% | +18.8% |
Valuation Metrics
Evenly matched — SSYS and RBOT and TRVI and ISRG each lead in 1 of 4 comparable metrics.
Valuation Metrics
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $143M | $707M | $3M | $2.0B | $161.1B |
| Enterprise ValueMkt cap + debt − cash | $140M | $639M | $8M | $2.0B | $158.0B |
| Trailing P/EPrice ÷ TTM EPS | -2.92x | -6.41x | -0.06x | -48.45x | 57.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 69.79x | — | — | 43.84x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 2.65x |
| EV / EBITDAEnterprise value multiple | — | — | — | — | 43.62x |
| Price / SalesMarket cap ÷ Revenue | — | 1.28x | — | — | 16.00x |
| Price / BookPrice ÷ Book value/share | 9.44x | 0.79x | 0.30x | 11.13x | 9.17x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 64.67x |
Profitability & Efficiency
ISRG leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-3 for RBOT. TRVI carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RBOT's 0.79x. On the Piotroski fundamental quality scale (0–9), SSYS scores 6/9 vs RBOT's 1/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -37.1% | -12.3% | -3.3% | -24.5% | +16.9% |
| ROA (TTM)Return on assets | -34.4% | -9.6% | -164.5% | -23.4% | +14.8% |
| ROICReturn on invested capital | -6.2% | -5.8% | -116.2% | -31.9% | +15.0% |
| ROCEReturn on capital employed | -2.9% | -6.6% | -134.6% | -34.7% | +16.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 1 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.03x | 0.03x | 0.79x | 0.00x | 0.02x |
| Net DebtTotal debt minus cash | -$3M | -$68M | $5M | -$18M | -$3.1B |
| Cash & Equiv.Liquid assets | $3M | $95M | $3M | $19M | $3.4B |
| Total DebtShort + long-term debt | $111,000 | $27M | $8M | $753,000 | $303M |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | — | — |
Total Returns (Dividends Reinvested)
TRVI leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TRVI five years ago would be worth $66,905 today (with dividends reinvested), compared to $16 for RBOT. Over the past 12 months, TRVI leads with a +111.0% total return vs RBOT's -94.1%. The 3-year compound annual growth rate (CAGR) favors TRVI at 64.6% vs RBOT's -80.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +0.9% | -9.0% | -80.6% | +18.2% | -19.3% |
| 1-Year ReturnPast 12 months | -15.1% | -15.6% | -94.1% | +111.0% | -15.4% |
| 3-Year ReturnCumulative with dividends | +85.2% | -42.9% | -99.2% | +346.0% | +49.6% |
| 5-Year ReturnCumulative with dividends | -69.7% | -59.1% | -99.8% | +569.0% | +58.7% |
| 10-Year ReturnCumulative with dividends | -99.4% | -60.6% | -99.8% | +78.1% | +554.2% |
| CAGR (3Y)Annualised 3-year return | +22.8% | -17.0% | -80.2% | +64.6% | +14.4% |
Risk & Volatility
Evenly matched — TRVI and ISRG each lead in 1 of 2 comparable metrics.
Risk & Volatility
ISRG is the less volatile stock with a 1.02 beta — it tends to amplify market swings less than RBOT's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TRVI currently trades 87.2% from its 52-week high vs RBOT's 3.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.85x | 1.79x | 1.92x | 1.06x | 1.02x |
| 52-Week HighHighest price in past year | $4.67 | $12.81 | $13.75 | $16.12 | $603.88 |
| 52-Week LowLowest price in past year | $1.60 | $7.34 | $0.35 | $5.38 | $427.84 |
| % of 52W HighCurrent price vs 52-week peak | +45.6% | +64.0% | +3.6% | +87.2% | +75.1% |
| RSI (14)Momentum oscillator 0–100 | 46.3 | 64.8 | 30.0 | 57.2 | 42.4 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 818K | 24K | 1.5M | 1.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MBOT as "Buy", SSYS as "Buy", TRVI as "Buy", ISRG as "Buy". Consensus price targets imply 158.2% upside for MBOT (target: $6) vs 37.0% for TRVI (target: $19).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | — | Buy | Buy |
| Price TargetConsensus 12-month target | $5.50 | $13.50 | — | $19.25 | $622.60 |
| # AnalystsCovering analysts | 3 | 36 | — | 17 | 55 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | +1.4% |
ISRG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TRVI leads in 1 (Total Returns). 2 tied.
MBOT vs SSYS vs RBOT vs TRVI vs ISRG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MBOT or SSYS or RBOT or TRVI or ISRG a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -3. 7% for Stratasys Ltd. (SSYS). Intuitive Surgical, Inc. (ISRG) offers the better valuation at 57. 6x trailing P/E (43. 8x forward), making it the more compelling value choice. Analysts rate Microbot Medical Inc. (MBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MBOT or SSYS or RBOT or TRVI or ISRG?
On forward P/E, Intuitive Surgical, Inc.
is actually cheaper at 43. 8x.
03Which is the better long-term investment — MBOT or SSYS or RBOT or TRVI or ISRG?
Over the past 5 years, Trevi Therapeutics, Inc.
(TRVI) delivered a total return of +569. 0%, compared to -99. 8% for Vicarious Surgical Inc. (RBOT). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus RBOT's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MBOT or SSYS or RBOT or TRVI or ISRG?
By beta (market sensitivity over 5 years), Intuitive Surgical, Inc.
(ISRG) is the lower-risk stock at 1. 02β versus Vicarious Surgical Inc. 's 1. 92β — meaning RBOT is approximately 89% more volatile than ISRG relative to the S&P 500. On balance sheet safety, Trevi Therapeutics, Inc. (TRVI) carries a lower debt/equity ratio of 0% versus 79% for Vicarious Surgical Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MBOT or SSYS or RBOT or TRVI or ISRG?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus -3. 7% for Stratasys Ltd. (SSYS). On earnings-per-share growth, the picture is similar: Trevi Therapeutics, Inc. grew EPS 38. 3% year-over-year, compared to 21. 2% for Vicarious Surgical Inc.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MBOT or SSYS or RBOT or TRVI or ISRG?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -18. 9% for Stratasys Ltd. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -10. 7% for SSYS. At the gross margin level — before operating expenses — ISRG leads at 66. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MBOT or SSYS or RBOT or TRVI or ISRG more undervalued right now?
On forward earnings alone, Intuitive Surgical, Inc.
(ISRG) trades at 43. 8x forward P/E versus 69. 8x for Stratasys Ltd. — 25. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MBOT: 158. 2% to $5. 50.
08Which pays a better dividend — MBOT or SSYS or RBOT or TRVI or ISRG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is MBOT or SSYS or RBOT or TRVI or ISRG better for a retirement portfolio?
For long-horizon retirement investors, Intuitive Surgical, Inc.
(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +554. 2% 10Y return). Vicarious Surgical Inc. (RBOT) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ISRG: +554. 2%, RBOT: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MBOT and SSYS and RBOT and TRVI and ISRG?
These companies operate in different sectors (MBOT (Healthcare) and SSYS (Technology) and RBOT (Healthcare) and TRVI (Healthcare) and ISRG (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: MBOT is a small-cap quality compounder stock; SSYS is a small-cap quality compounder stock; RBOT is a small-cap quality compounder stock; TRVI is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.